Manufacturers Testing Xarelto for 10 Additional Uses
Xarelto manufacturer, Janssen announced they would be stopping their COMPASS trial a year early. This trial is part of their Explorer research program to expand Xarelto to 10 more label uses. COMPASS trial was evaluating the efficacy and safety of the blood thinner for the prevention of major adverse cardiac events. This includes cardiovascular death, myocardial infarctions, and strokes in patients with coronary artery disease. The manufacturer said they are stopping the trial since the 27,000 patient trial showed overwhelming efficacy in relation to cardiovascular health.
This trial is Bayer and Janssen’s first step at extending Xarelto’s consumer reach. Bayer said the drug is currently the only non-vitamin K antagonist oral anticoagulant (NOAC) currently under assessment in this high-risk patient population. The company will present all data from the COMPASS trial at an upcoming medical meeting. Xarelto is an orally administered drug. It helps prevent blood from clotting by inhibiting Factor Xa. This is necessary for the formation of thrombin and fibrin, key components in blood clot formation.
The drug is already on the market for reducing the risk of stroke and blood clots in people with atrial fibrillation, deep vein thrombosis or pulmonary embolism. It also is used to help prevent recurrence and to reduce the risk of blood clots in those who just t had knee or hip replacement surgery.
Dangers of Xarelto
There is no antidote to reverse the anti-clotting effect of Xarelto in an emergency. This means doctors and surgeons may have limited options. A treatable injury for most people can be a fatal one for Xarelto users.
Some of the potentially fatal conditions Xarelto users have suffered include gastrointestinal bleeding, brain hemorrhaging, kidney bleeding, rectal bleeding, and other internal bleeding events.
Not So Efficient
Unlike trials financed by Xarelto manufacturers, outside researchers found shocking results when people take the drug. Institute For Safe Medication Practices (ISMP) examined all the adverse events submitted to the FDA after patients took Xarelto. They also examined all the adverse events reported to the FDA after patients took the coagulant. Then, they determined that Xarelto failed to prevent pulmonary embolism, caused uncontrollable bleeding, and wasn’t very efficient. In fact, over a thousand patients died. Another 10,000 were injured.
If you or a loved one has suffered a serious bleeding incident due to Xarelto, contact us today. The Michael Brady Lynch Firm may be the only law firm to get you the resources you need to move on with your life.
Nothing can take back what has happened. But it’s very likely this ordeal has placed a huge burden on your family both financially and emotionally. You don’t deserve this, and you need to seek compensation for it.